Cell and Gene Therapy Catapult (CGT Catapult) officially opened its unique cell and gene therapy manufacturing centre in Stevenage, UK. Backed by investment from UK Government, the centre will support and develop the rapidly growing global cell and gene therapy industry.
The centre, operating to Good Manufacturing Practice (GMP) standards for clinical product manufacturing, will provide the global Advanced Therapeutics industry with the infrastructure to develop manufacturing capability and systems for large-scale cell and gene therapy clinical studies, and accelerate commercialisation. The centre will also supply the network of world-first, UK-based Advanced Therapies Treatment Centres (ATTCs) formed as part of the government’s investment through its Industrial Strategy Challenge Fund in medicines manufacturing.
Cell and gene therapies offer revolutionary treatments which repair, replace, regenerate and re-engineer genes, cells and tissues to restore normal function or enhance their ability to fight diseases, like cancer. By enabling collaborators at the centre to turn their cell and gene therapy innovations into commercially viable new medicines, the CGT Catapult is supporting the routine delivery of these therapies to hospitals, clinics and patients globally.
The manufacturing centre is located within the rapidly growing European cell and gene therapy cluster at the Stevenage BioScience Catalyst. The campus is a joint venture between the Department for Business Innovation and Skills, GlaxoSmithKline, Wellcome biomedical research charity and Innovate UK innovation agency.